| ATNM |
Actinium Pharmaceuticals, Inc. |
72%
|
e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clin… |
| ATNM |
Actinium Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ATNM graph: Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible … |
| AZN |
AstraZeneca PLC |
72%
|
e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clin… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible f… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clin… |
| BSX |
Boston Scientific Corporation |
72%
|
e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clin… |
| BSX |
Boston Scientific Corporation |
72%
|
Reciprocal relationship from BSX graph: Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible f… |
| CATX |
Perspective Therapeutics, Inc. |
72%
|
Reciprocal relationship from CATX graph: Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible … |
| CATX |
Perspective Therapeutics, Inc. |
72%
|
e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clin… |
| NBTX |
Nanobiotix S.A. |
72%
|
e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clin… |
| NBTX |
Nanobiotix S.A. |
72%
|
Reciprocal relationship from NBTX graph: Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible … |
| TLX |
Telix Pharmaceuticals Limited |
72%
|
e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clin… |
| TLX |
Telix Pharmaceuticals Limited |
72%
|
Reciprocal relationship from TLX graph: Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible f… |
| ALPHA-TAU-MEDICAL-CANADA-INC |
ALPHA-TAU-MEDICAL-CANADA-INC |
62%
|
NOTE 1: - GENERAL a. Company description: Alpha Tau Medical Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization… |
| ALPHA-TAU-MEDICAL-INC |
ALPHA-TAU-MEDICAL-INC |
62%
|
NOTE 1: - GENERAL a. Company description: Alpha Tau Medical Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization… |
| ALTHERA-MEDICAL-LTD |
ALTHERA-MEDICAL-LTD |
62%
|
NOTE 1: - GENERAL a. Company description: Alpha Tau Medical Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization… |
| ATM-CANADA-INC |
ATM-CANADA-INC |
62%
|
NOTE 1: - GENERAL a. Company description: Alpha Tau Medical Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ct to continue to incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support our continuing operations and pursue our gr… |
| C-ORGANIZATIONAL-STRUCTURE-ALPHA-TAU-MEDICAL-LTD |
C-ORGANIZATIONAL-STRUCTURE-ALPHA-TAU-MEDICAL-LTD |
62%
|
evices are reimbursed under state-run healthcare schemes. More and more, local, product specific reimbursement law is applied as an overlay to medical device regulation, which has provided an additio… |
| COVERED-EXECUTIVES-COMPANY |
COVERED-EXECUTIVES-COMPANY |
62%
|
, including Mila-Media, BeTerrific! and others. In 2014, Dr. Milch invested in the first biopharma spinout from well-known genomics research leader Jackson Laboratories, Cyteir Therapeutics, with co-… |
| HEALTHCARE-CAPITAL-CORP |
HEALTHCARE-CAPITAL-CORP |
62%
|
NOTE 1: - GENERAL a. Company description: Alpha Tau Medical Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization… |
| MIM-SOFTWARE-INC |
MIM-SOFTWARE-INC |
62%
|
esearch, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable compet… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
y maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to poten… |
